(Total Views: 142)
Posted On: 11/30/2022 9:20:03 AM
Post# of 23607
$NBIO with the Biotechnology space rotating toward a more acquisition friendly dynamic, investors may benefit from a studied focus on likely takeout candidates - particularly early-stage pipelines with recent identifiable traction targeting large end markets.
One such example is Nascent Biotech Inc. (OTCMKTS:NBIO), an emerging player in the $4 billion oncology drug development space.
NBIO is certainly early-stage: its flagship drug is just heading toward Phase 2 clinical research, right in the sweet spot for dealmaking as a potential acquisition target as deals pick up pace this cycle. https://www.marketwatch.com/press-release/fis...re_twitter
One such example is Nascent Biotech Inc. (OTCMKTS:NBIO), an emerging player in the $4 billion oncology drug development space.
NBIO is certainly early-stage: its flagship drug is just heading toward Phase 2 clinical research, right in the sweet spot for dealmaking as a potential acquisition target as deals pick up pace this cycle. https://www.marketwatch.com/press-release/fis...re_twitter
(0)
(0)Scroll down for more posts ▼
